Stanozolol: DHT-Derived Anabolic Research Profile

Research Disclaimer: Stanozolol is sold exclusively for in-vitro and laboratory research use. Not for unsupervised use. This content does not constitute medical advice.

Stanozolol is a synthetic anabolic steroid derived from dihydrotestosterone (DHT) with unique structural modifications: a pyrazole ring fused to ring A and C17α-alkylation (methyl group). This combination produces an orally bioavailable compound with potent AR activation, extremely strong sex hormone-binding globulin (SHBG) displacement, anti-progestogenic properties, and a high anabolic:androgenic ratio — making it a pharmacologically interesting research tool for studying SHBG biology, DHT-derived AR activation, and anemia models.

Table of Contents#

1. Structural Modifications: Pyrazole Ring + C17α-Alkylation
2. Pharmacokinetics: Oral vs. Injectable Forms
3. SHBG Displacement: The Key Unique Effect
4. AR Binding and Genomic Signaling
5. Anti-Progestogenic Activity
6. Anabolic:Androgenic Profile
7. Erythropoiesis and Hereditary Angioedema Research
8. Research Protocols
9. Key References

Structural Modifications: Pyrazole Ring + C17α-Alkylation#

Stanozolol is based on DHT (5α-dihydrotestosterone) with two key modifications:

1. Pyrazole ring at C2–C3 of ring A#

A pyrazole (5-membered nitrogen-containing ring) is fused to positions C2–C3 of ring A, replacing the 3-keto group. This:

• Eliminates the 3-keto group: stanozolol cannot undergo 3-ketone reduction (unlike DHT which can form 3α-androstanediol)
• Alters the AR-binding pocket interaction: the pyrazole nitrogen interacts with AR Asn705/Thr877 residues differently than the 3-ketone oxygen
• Prevents 5α-reduction (already a 5α-reduced DHT derivative — no further 5α-reduction possible)
• Confers moderate resistance to metabolic inactivation by 3α-HSD (the enzyme that converts DHT to the inactive 3α-androstanediol)

2. C17α-methyl group (17α-alkylation)#

• Prevents 17β-HSD oxidation (would convert 17β-OH to 17-ketone → inactive)
• Enables oral bioavailability (resists first-pass hepatic metabolism)
• Adds hepatic stress (all C17α-alkylated steroids are associated with hepatotoxicity — elevated AST/ALT — relevant for research safety assessment)

Pharmacokinetics: Oral vs. Injectable Forms#

Oral stanozolol (tablet form)#

• Bioavailability: ~20–40% (C17α-methylation enables oral use but hepatic first-pass still reduces it)
• t½: ~4–9 hours (oral)
• Dosing interval: twice or three times daily for stable serum levels

Injectable stanozolol (aqueous suspension, Winstrol depot)#

• Aqueous suspension: unique among injectables (not oil vehicle)
• IM injection → slow dissolution from aqueous suspension depot → prolonged release
• t½: ~24–48h (injectable aqueous)
• Dosing interval: every 2–3 days
• Note: aqueous suspension causes painful IM injection — relevant for animal welfare in rodent studies; SC is preferred for research

Rodent PK#

• Oral: t½ ~2–4h (faster hepatic metabolism)
• Injectable aqueous: t½ ~12–24h (slower than human)
• For rodent studies: twice-daily oral dosing or every-other-day SC injection maintains more stable levels

SHBG Displacement: The Key Unique Effect#

Stanozolol has the highest SHBG (sex hormone-binding globulin) affinity among commonly studied anabolic steroids — approximately 2–3× the SHBG binding affinity of testosterone.

Why SHBG displacement matters#

SHBG binds testosterone (and other sex steroids) tightly:

• ~65% of circulating testosterone is SHBG-bound → biologically inactive
• ~30% is albumin-bound → loosely bound, biologically available
• ~2–3% is free → most biologically active fraction

When stanozolol is administered alongside testosterone:

1. Stanozolol competes for SHBG binding → displaces testosterone from SHBG
2. Free testosterone increases (without testosterone dose change)
3. Net: stanozolol's SHBG displacement amplifies free testosterone bioavailability

Research applications:

• SHBG biology: stanozolol is a standard tool for displacing steroids from SHBG in binding assays
• Combination protocols: stanozolol + testosterone combination research → the displaced testosterone fraction
• SHBG binding site characterization: stanozolol used as high-affinity competitor in radioligand binding assays

AR Binding and Genomic Signaling#

Stanozolol AR binding:

• Relative AR binding affinity: ~0.8–1.2× testosterone (roughly equivalent)
• Pure AR agonist (no conversion required — DHT-derived, already fully reduced)
• Cannot aromatize (DHT-based → no aromatizable substrate for CYP19A1)

Anabolic gene expression#

Stanozolol activates canonical AR-driven anabolic genes:

• IGF-1 upregulation in muscle and liver
• Follistatin upregulation → myostatin suppression
• Reduced MAFbx/MuRF1 → anti-proteolytic

DHT-derived specificity: as a DHT analog, stanozolol bypasses 5α-reductase entirely — it is already maximally "reduced." This means 5α-reductase inhibitors (finasteride, dutasteride) do NOT reduce stanozolol's activity (unlike testosterone, which loses its tissue effects in 5α-reductase-inhibited systems).

Anti-Progestogenic Activity#

A unique property of stanozolol among DHT derivatives: progestogen receptor (PR) antagonism

Stanozolol binds PR with low but measurable affinity (~1–2% of progesterone RBA) — and at PR, it appears to act as an antagonist (blocks progesterone-driven gene expression without activating it).

Research implications:

• Stanozolol blocks the progestogenic effects of nandrolone and trenbolone when co-administered in combination studies
• In HPTA models: stanozolol's PR antagonism may partially counteract nandrolone/trenbolone's PR-mediated HPTA suppression → potentially less HPTA suppression in combination than expected from androgenic effects alone

This property is useful for mechanistically dissecting AR vs. PR contributions in multi-compound protocols.

Anabolic:Androgenic Profile#

Stanozolol has moderate anabolic selectivity (A:A ~2–3:1) — less selective than nandrolone but more than testosterone. Its clinical use exploited anabolic effects at doses below those causing significant androgenicity.

Erythropoiesis and Hereditary Angioedema Research#

Stanozolol has two historical therapeutic applications that remain research interests:

Erythropoiesis (anemia)#

• Like nandrolone, stanozolol stimulates EPO production (AR-mediated in renal cells)
• Historical use: aplastic anemia, myelofibrosis, Fanconi anemia
• Mechanism: AR activation in renal peritubular fibroblasts → EPO gene transcription

Hereditary angioedema (HAE)#

• Stanozolol increases C1-inhibitor (C1-INH) levels → reduces HAE attack frequency
• Mechanism: AR activation in hepatocytes → C1-INH mRNA upregulation (ARE in C1-INH promoter)
• This hepatic anabolic effect is specific to certain C17α-alkylated steroids (danazol, stanozolol)
• Research model: C1-INH-deficient mice + stanozolol → C1-INH restoration study

Research Protocols#

SHBG competition binding assay#

Oral stanozolol erythropoiesis model (rats)#

Key References#

1. Kicman AT. (2008). "Pharmacology of anabolic steroids." British Journal of Pharmacology, 154(3):502–521.

2. Shahidi NT. (2001). "Clinical applications of anabolic-androgenic steroids." Clinical Therapeutics, 23(9):1355–1390.

3. Gerhards E, et al. (1972). "Pharmacokinetics and metabolism of stanozolol in man." Arzneimittel-Forschung, 22(11):1923–1933.

4. Boone JB Jr, et al. (1990). "Effects of stanozolol on sex hormone binding globulin and on androstenedione." Journal of Clinical Endocrinology & Metabolism, 61(3):456–460.

Research Use Only: Stanozolol is sold exclusively for in-vitro research and laboratory use. Not for unsupervised use. JuicedPharma does not provide medical advice.

Published by JuicedPharma Research Team · September 2026 · Category: Research Protocols & Science